

JP

2024 APR 15 AM 9:47

STATE OF OHIO
Executive Department

OFFICE OF THE GOVERNOR

Columbus

I, Mike DeWine, Governor of the State of Ohio, do hereby appoint Harish Kakarala, from Akron, Summit County, Ohio, as a Member of the State Medical Board for a new term beginning March 29, 2024 and ending at the close of business March 18, 2029, replacing Harish Kakarala, whose term expired.



IN WITNESS WHEREOF, I have hereunto subscribed my name and caused the Great Seal of the State of Ohio to be affixed, at Columbus, this 29th day of March in the year of our Lord, Two Thousand and Twenty Four.



Mike DeWine
Governor

HARISH KAKARALA, M.D. FACP, FCCP

C: (216) 401-3850

BUSINESS:

2022- CEO/Founder, Summit Rehabilitation (Private Medical Consulting)

2015 – 2022 Cleveland Clinic Akron General 1 Akron General Ave Akron, OH 44307

2002-2015 NPCS 224 West Exchange St Suite 380 Akron, Ohio 44307

BOARD CERTIFICATIONS:

1999 – Present ABIM: Internal Medicine

2001 – Present ABIM: Pulmonary Disease

2002 – Present ABIM: Critical Care Medicine

2011-Present ABIM: Sleep Medicine

POSITIONS:

2004 – Present Clinical Professor of Internal Medicine, NEOMED

2005 –2006 Professional Development Advisor, NEOMED

2006 – 2010 Section Chief of Critical Care Medicine, Cleveland Clinic Akron General

2015 – 2017 Program Director of Internal Medicine Residency, Cleveland Clinic Akron General

2016 – Present Clinical Assistant Professor, OUHCOM

2019-Present Physician Member, State Medical Board of Ohio

2019-Present State of Ohio Respiratory Care Advisory Council

2019-Present Fellow, Federation of State Medical Boards

EDUCATION:

1989 – 1992 University of Akron (Akron, OH) Bachelor of Science Natural Sciences, Minor in Chemistry

1992 – 1996 Northeastern Ohio Medical University (NEOMED) (Rootstown, Ohio) M.D.

1996 – 1999 Summa Health System (Akron, Ohio) Internal Medicine Internship and Residency

1999 – 2002 University of Illinois at Chicago (UIC) (Chicago, Illinois) Pulmonary/Critical Care/Sleep Medicine Fellowship

HONORS:

1996 – 1997 Nominated for Intern of the Year, Summa Health System

1997 – 1998 Nominated for Resident of the Year, Summa Health System

1998 – 1999 Nominated for Resident of the Year, Summa Health System

2001 – 2002 Chief Fellow, Pulmonary/Critical Care Fellowship, University of Illinois at Chicago

2004, 2008 Certificate of Teaching Appreciation, NEOMED

2020 Teaching Attending of The Year, Department of Medicine, Cleveland Clinic Akron General

ORGANIZATIONS:

1996 – 1999 Residency Council Committee, Summa Health System

1996 – 1999 Critical Care Committee, Summa Health System

1996 – 2000 American College of Physicians: Associate Member

1997 – Present American Thoracic Society: Member

1999 – 2002 American College of Chest Physicians: Affiliate Member

2002 – 2004 American College of Chest Physicians: Member

2004 – Present Fellow of the American College of Chest Physicians

2016 – Present Fellow of the American College of Physicians

COMMITTEES:

2002 – 2010 Cleveland Clinic Akron General Stat Page Committee

2003 – 2010 Cleveland Clinic Akron General Endoscopy Committee

2003 – 2010 Cleveland Clinic Akron General Respiratory Care Committee

2006 – 2010 Cleveland Clinic Akron General Critical Care Committee

2006 – 2010 Cleveland Clinic Akron General Pharmaceuticals & Therapeutics

2006 – 2010 Cleveland Clinic Akron General IRRB

2007 – 2008 Cleveland Clinic Akron General Dept. of Medicine QI Committee

RESEARCH, CO-INVESTIGATOR:

A 12 Week, International, Multicenter, Double-Blind, Randomized. Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension (Protocol TDE –PH-302 (10/09-Present)

Spiration 01675- A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV Valve System for the Treatment of Severe Emphysema (1/09)

A Phase II Study of the 20 ML Biologic Lung Volume Reduction (BLVR) System in Patients with Advanced Upper Lobe Predominant Emphysema (12/07-12/08)

AERIS-HOMOGENEOUS: Phase 2 Study of the 20 mL Biologic Lung Volume Reduction System (BLVR) in Patients with Homogeneous or Upper Lobe Predominant Emphysema (4/08-10/9)

Phase 2, Open-Label, Non-Comparative Study of Doripenem in the Treatment of Nosocomial and Ventilator-Associated Pneumonia in Hospitals Where Pseudomonas Aeruginosa May be a Prevalent Pathogen (7/07-3/09)

Primo CABG II – A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study of 2mg/kg Bolus Plus 24 hour 0.05 mg/kg/hr Infusion of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass.(5/07-2/08)

EVEREST-OTSUKA-TOLVAPTAN-Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure. Protocol #156-03-236.(9/01-7/04)

THERAVANCE-A Phase 3, Randomized, Double-Blind, Parallel-Group, MultiNational Trial of Intravenous Teleavancin Vs. Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus Aureus. (7/02-7/05)

NAPA-SCIOS-A Pilot, Multicenter, Randomized, Double-blind, Placebo- Controlled Study to Evaluate Nesiritide Infusion, Initiated Post Induction of Anesthesia, in the Management of Coronary Artery Bypass Graft (CABG) Patients Requiring Cardiopulmonary Bypass (CPB)-A014 (3/04-7/05)

APNEA-CHF-effects of Cardiac Resynchronization Therapy on Sleep Disordered Breathing in Heart Failure Patients.(1/03-1/04)

AERIS PHASE 3 Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients with Advanced Upper Lobe Predominant Emphysema (5/08-12/08)

DORIINI 2002 Ortho McNeil Janssen Scientific Affairs, LLC., Clinical Protocol A Phase 2, Open Label, Non-Comparative Study of Doripenem in the Treatment of Nosocomial and Ventilator-Associated Pneumonia in hospitals where Pseudomonas Aeruginosa may be a Prevalent Pathogen 2005-2007

THE FUSION II Follow up Serial Infusions of Natrecor® (nesiritide) for The Management of Patients with Heart Failure 2004-2007

CAPTIVATE A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-blind, Three-Arm Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) Administration in Subjects with Severe Community-Acquired Pneumonia 2004-2006

GOVERNOR'S APPOINTMENTS TO BOARDS AND COMMISSIONS

Appointment Date: 3/29/2024

Name of Appointee: Harish Kakarala

Address: 3588 N. Shore Dr
Akron, OH 44333
Summit County
(H): 3306700460
(W):
(M): 2164013850
(E): Hkakarala@yahoo.com

Name of Commission: State Medical Board
Stephanie Loucka
Executive Director
30 E. Broad St., 3rd Floor
Columbus, OH 43215
(P): (614) 644-4449
(E): Stephanie.Loucka@med.ohio.gov

Term Begins: 3/19/2024

Term Ends: 3/18/2029

Party Affiliation: Republican

Senate Confirmation: Appointed by the Governor, confirmed by the Senate

Financial Disclosure: Public disclosure required

Vice: Harish Kakarala

